Two kinds of endometrial neoplasia arising from different origins in the uterine corpus: comparison of p53 expression and sex steroid receptor status

Koshiyama M, Masafumi Koshiyama, Michio Ueta, Ueta M
European journal of obstetrics, gynecology, and reproductive biology · 2002 · vol. 104(2) , pp. 167–170 · doi:10.1016/s0301-2115(02)00104-5 · PMID:12206933 · W2055940770
article OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-09 ⓘ

This study compared p53 expression and sex steroid receptor status in two distinct types of endometrial neoplasia, investigating their different origins within the uterine corpus.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

This study presents a case of endometrial clear cell adenocarcinoma complicated by complex atypical glandular hyperplasia surrounded by adenomyosis in the uterine myometrium. The former was immuno-negative for estrogen receptor (ER) and positive for p53, whereas both of the latter were immuno-positive for ER and negative for p53. Therefore, there were two kinds of neoplasia arising from different origins in the uterine corpus.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Adenocarcinoma, Clear Cell Endometrial Neoplasms Endometriosis Receptors, Estrogen Tumor Suppressor Protein p53 Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Adenocarcinoma, Clear Cell Aged Endometrial Hyperplasia Endometrial Hyperplasia Endometrial Hyperplasia Endometrial Hyperplasia Endometrial Neoplasms Endometrial Neoplasms Endometrial Neoplasms Endometriosis Endometriosis Endometriosis Female

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

References (16)

Source provenance

europepmc
last seen: 2026-08-29T06:12:09.280863+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:13:01.552487+00:00
License: CC0 · commercial use OK